Management of the liver transplant patient

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 6, 2009, Pages 631-647

  Gelb, Bruce ^b   Feng, Sandy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Complication; Disease recurrence; End stage liver disease; Health maintenance; Immunosuppression; Liver transplantation; Postoperative management; Rejection

Indexed keywords

ALEMTUZUMAB; ANTICOAGULANT AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; DAPSONE; FIBRINOLYTIC AGENT; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; OKT 3; PEGINTERFERON ALPHA; PENTAMIDINE; PREDNISONE; RAPAMYCIN; RIBAVIRIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALGANCICLOVIR;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ANASTOMOSIS LEAKAGE; ANEMIA; ARTERY THROMBOSIS; BALLOON DILATATION; BILE DUCT OBSTRUCTION; BILOMA; BONE DISEASE; BONE MARROW SUPPRESSION; CATARACT; CHOLEDOCHOJEJUNOSTOMY; CHRONIC GRAFT REJECTION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DOPPLER FLOWMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSLIPIDEMIA; EPSTEIN BARR VIRUS; EXERCISE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GOUT; GRAFT OCCLUSION; GRAFT RECIPIENT; GROWTH RETARDATION; HEPATITIS B; HEPATITIS C; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALAISE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; MOUTH ULCER; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OBESITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL EDEMA; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PORTAL VEIN THROMBOSIS; POSTOPERATIVE CARE; RENAL REPLACEMENT THERAPY; RETRANSPLANTATION; REVIEW; SIDE EFFECT; STENT; SURGICAL DRAINAGE; SURVIVAL RATE; THERAPY RESISTANCE; THROMBECTOMY; THROMBOCYTOPENIA; TREMOR; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE CARE;

EID: 73549106791     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.58     Document Type: Review

References (122)

1. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig. Dis. Sci. 31(5), 468-475 (1986).
2. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg. Gynecol. Obstet. 117, 659-676 (1963).
3. National Institutes of Health Consensus Development Conference Statement: liver transplantation - June 20-23, 1983. Hepatology 4(1 Suppl.), S107-S110 (1984).
4. United Network of Organ Sharing. 2007 OPTN/SRTR Annual Report. Department of Health and Human Services, DC, USA (2007).
5. Yoshida EM, Lake JR. Selection of patients for liver transplantation in 1997 and beyond. Clin. Liver Dis. 1(2), 247-261, vii (1997).
6. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. 2007 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, MD, USA (2007).
7. Briceno J, Marchal T, Padillo J, Solorzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation 74(4), 522-526 (2002).
8. D'Alessandro AM, Kalayoglu M, Sollinger HW et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 51(1), 157-163 (1991).
9. Sanchez-Bueno F, Robles R, Ramirez P et al. Hepatic artery complications after liver transplantation. Clin. Transplant. 8(4), 399-404 (1994).
10. Stange BJ, Glanemann M, Nuessler NC, Settmacher U, Steinmuller T, Neuhaus P. Hepatic artery thrombosis after adult liver transplantation. Liver Transpl. 9(6), 612-620 (2003).
11. Silva MA, Jambulingam PS, Gunson BK et al. Hepatic artery thrombosis following orthotopic liver transplantation: a 10-year experience from a single centre in the United Kingdom. Liver Transpl. 12(1), 146-151 (2006).
12. Drazan K, Shaked A, Olthoff KM et al. Etiology and management of symptomatic adult hepatic artery thrombosis after orthotopic liver transplantation (OLT). Am. Surg. 62(3), 237-240 (1996).
13. Oh CK, Pelletier SJ, Sawyer RG et al. Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation 71(6), 767-772 (2001).
14. You S, He XS, Hu AB et al. The analysis of portal vein thrombosis following orthotopic liver transplantation. Zhonghua Wai Ke Za Zhi 46(3), 176-178 (2008).
15. Lerut J, Tzakis AG, Bron K et al. Complications of venous reconstruction in human orthotopic liver transplantation. Ann. Surg. 205(4), 404-414 (1987).
16. Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl. 7(11 Suppl. 1), S60-S73 (2001). • Comprehensive review of the diagnosis and management of hepatic graft dysfunction in the intermediate- to long-term phase.
17. Cherukuri R, Haskal ZJ, Naji A, Shaked A. Percutaneous thrombolysis and stent placement for the treatment of portal vein thrombosis after liver transplantation: long-term follow-up. Transplantation 65(8), 1124-1126 (1998).
18. Moser MA, Wall WJ. Management of biliary problems after liver transplantation. Liver Transpl. 7(11 Suppl. 1), S46-S52 (2001).
19. Qian YB, Liu CL, Lo CM, Fan ST. Risk factors for biliary complications after liver transplantation. Arch. Surg. 139(10), 1101-1105 (2004).
20. Gondolesi GE, Varotti G, Florman SS et al. Biliary complications in 96 consecutive right lobe living donor transplant recipients. Transplantation 77(12), 1842-1848 (2004).
21. Shah SA, Grant DR, McGilvray ID et al. Biliary strictures in 130 consecutive right lobe living donor liver transplant recipients: results of a Western center. Am. J. Transplant. 7(1), 161-167 (2007).
22. Osorio RW, Freise CE, Stock PG et al. Nonoperative management of biliary leaks after orthotopic liver transplantation. Transplantation 55(5), 1074-1077 (1993).
23. Righi D, Franchello A, Ricchiuti A et al. Safety and efficacy of the percutaneous treatment of bile leaks in hepaticojejunostomy or split-liver transplantation without dilatation of the biliary tree. Liver Transpl. 14(5), 611-615 (2008).
24. Sanchez-Urdazpal L, Gores GJ, Ward EM et al. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology 17(4), 605-609 (1993).
25. Rossi AF, Grosso C, Zanasi G et al. Long-term efficacy of endoscopic stenting in patients with stricture of the biliary anastomosis after orthotopic liver transplantation. Endoscopy 30(4), 360-366 (1998).
26. Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin. Biol. Ther. 7(1), 137-148 (2007).
27. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. 2003 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, MD, USA (2003).
28. O'Grady JG. Corticosteroid-free strategies in liver transplantation. Drugs 66(14), 1853-1862 (2006).
29. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 75(8), 1396-1399 (2003).
30. Levy GA. Long-term immunosuppression and drug interactions. Liver Transpl. 7(11 Suppl. 1), S53-S59 (2001).
31. Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin. Exp. Immunol. 139(1), 2-10 (2005).
32. Moreno JM, Rubio E, Pons F et al. Usefulness of mycophenolate mofetil in patients with chronic renal insufficiency after liver transplantation. Transplant. Proc. 35(2), 715-717 (2003).
33. Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl. 11(3), 267-280 (2005). • Good overview of immunosuppressive medications, their mechanisms of action and complications. This article will mostly be of interest to readers outside the field of transplantation or with limited knowledge of these medications.
34. Garcia CE, Ribeiro HB, Garcia RL et al. Mycophenolate mofetil in stable liver transplant patients with calcineurin inhibitor-induced renal impairment: single-center experience. Transplant. Proc. 35(3), 1131-1132 (2003).
35. Beckebaum S, Cicinnati VR, Klein CG et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant. Proc. 36(9), 2671-2674 (2004).
36. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl. 7(6), 473-484 (2001).
37. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67(7), 1036-1042 (1999).
38. Trotter JF. Sirolimus in liver transplantation. Transplant. Proc. 35(3 Suppl.), S193-S200 (2003).
39. Shiffman ML, Saab S, Feng S et al. Liver and intestine transplantation in the United States, 1995-2004. Am. J. Transplant. 6(5 Pt 2), 1170-1187 (2006).
40. Montalbano M, Neff GW, Yamashiki N et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 78(2), 264-268 (2004).
41. Hayry P. Intragraft events in allograft destruction. Transplantation 38(1), 1-6 (1984).
42. Seiler CA, Renner EL, Czerniak A, Didonna D, Buchler MW, Reichen J. Early acute cellular rejection: no effect on late hepatic allograft function in man. Transpl. Int. 12(3), 195-201 (1999).
43. International Working Party. Terminology for hepatic allograft rejection. Hepatology 22(2), 648-654 (1995).
44. Urbani L, Mazzoni A, De Simone P et al. Treatment of antibody-mediated rejection with high-dose immunoglobulins in ABO-incompatible liver transplant recipient. Transpl. Int. 20(5), 467-470 (2007).
45. Vierling JM. Immunologic mechanisms of hepatic allograft rejection. Semin. Liver Dis. 12(1), 16-27 (1992).
46. Wiesner RH, Demetris AJ, Belle SH et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28(3), 638-645 (1998).
47. Uemura T, Ikegami T, Sanchez EQ et al. Late acute rejection after liver transplantation impacts patient survival. Clin. Transplant. 22(3), 316-323 (2008).
48. Bahra M, Neumann UP, Jacob D et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc. 37(4), 1700-1702 (2005).
49. Jain A, Reyes J, Kashyap R et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann. Surg. 230(3), 441-448; discussion 448-449 (1999). •• Large study showing excellent long-term outcomes with tacrolimus.
50. Wiesner RH, Batts KP, Krom RA. Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. Liver Transpl. Surg. 5(5), 388-400 (1999).
51. Jain A, Demetris AJ, Kashyap R et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl. 7(7), 623-630 (2001).
52. Freese DK, Snover DC, Sharp HL, Gross CR, Savick SK, Payne WD. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology 13(5), 882-891 (1991).
53. Trotter JF, Levi M, Steinberg T, Lancaster J. Absence of Pneumocystis jiroveci pneumonia in liver transplantation recipients receiving short-term (3-month) prophylaxis. Transpl. Infect. Dis. 10(5), 369-371 (2008).
54. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am. J. Transplant. 8(2), 426-431 (2008).
55. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365(9477), 2105-2115 (2005).
56. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N. Engl. J. Med. 338(24), 1741-1751 (1998). •• Excellent comprehensive review of the timing, diagnosis and therapeutic rationale of managing infection in the transplant population.
57. Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 21(5), 1328-1336 (1995).
58. Paya CV. Fungal infections in solid-organ transplantation. Clin. Infect. Dis. 16(5), 677-688 (1993).
59. Castaldo P, Stratta RJ, Wood RP et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch. Surg. 126(2), 149-156 (1991).
60. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin. Infect. Dis. 43(9), 1143-1151 (2006).
61. Sampathkumar P, Paya CV. Management of cytomegalovirus infection after liver transplantation. Liver Transpl. 6(2), 144-156 (2000).
62. Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A. Posttransplantation lymphoproliferative disorder - the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl. 13(6), 904-912 (2007). • Describes the evolution and changing spectrum of Epstein-Barr virus involvement in post-transplant lymphoproliferative disorder.
63. Jain A, Nalesnik M, Reyes J et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann. Surg. 236(4), 429-436; discussion 436-427 (2002).
64. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am. J. Transplant. 6(5 Part 1), 1017-1024 (2006).
65. Elstrom RL, Andreadis C, Aqui NA et al. Treatment of PTLD with rituximab or chemotherapy. Am. J. Transplant. 6(3), 569-576 (2006).
66. Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 345(1), 41-52 (2001).
67. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 9(11), S1-S9 (2003). •• Consensus guiding current management of hepatitis C virus in the liver transplant recipient population.
68. Feray C, Caccamo L, Alexander GJ et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) group. Gastroenterology 117(3), 619-625 (1999).
69. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 334(13), 815-820 (1996).
70. 2a and ribavirin for recurrent hepatitis C after liver transplantation. Transplant. Proc. 37(10), 4403-4405 (2005).
71. 2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol. Ther. 28(4), 450-457 (2008).
72. Toniutto P, Fabris C, Fumo E et al. Pegylated versus standard interferon-α in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. J. Gastroenterol. Hepatol. 20(4), 577-582 (2005).
73. Biggins SW, Terrault NA. Management of recurrent hepatitis C in liver transplant recipients. Infect. Dis. Clin. North Am. 20(1), 155-174 (2006).
74. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 12(8), 1192-1204 (2006).
75. Davis GL, Nelson DR, Terrault N et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 11(8), 941-949 (2005).
76. Galun E, Terrault NA, Eren R et al. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J. Hepatol. 46(1), 37-44 (2007).
77. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32(6), 1189-1195 (2000).
78. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132(3), 931-937 (2007). • Shows potentially significant cost savings by using lower doses of hepatitis B immunoglobulin.
79. Angus PW, McCaughan GW, Gane EJ et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 6(4), 429-433 (2000).
80. Yao F OR, Roberts J, Poordad F, Briceno M, Garcia-Kennedy R, Gish R. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl. 5(6), 491-496 (2003).
81. Sylvestre PB, Batts KP, Burgart LJ, Poterucha JJ, Wiesner RH. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl. 9(10), 1086-1093 (2003).
82. Graziadei IW, Wiesner RH, Batts KP et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29(4), 1050-1056 (1999).
83. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 68(2), 253-256 (1999).
84. Reich DJ, Fiel I, Guarrera JV et al. Liver transplantation for autoimmune hepatitis. Hepatology 32(4 Part 1), 693-700 (2000).
85. Contos MJ, Cales W, Sterling RK et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 7(4), 363-373 (2001).
86. Krawitt EL. Autoimmune hepatitis. N. Engl. J. Med. 354(1), 54-66 (2006).
87. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J. Hepatol. 40(1), 3-7 (2004).
88. McCashland TM. Posttransplantation care: role of the primary care physician versus transplant center. Liver Transpl. 7(11 Suppl. 1), S2-S12 (2001).
89. Sheiner PA, Magliocca JF, Bodian CA et al. Long-term medical complications in patients surviving ≥ 5 years after liver transplant. Transplantation 69(5), 781-789 (2000).
90. Textor SC, Canzanello VJ, Taler SJ, Schwartz L, Augustine J. Hypertension after liver transplantation. Liver Transpl. Surg. 1(5 Suppl. 1), 20-28 (1995).
91. Textor SC. De novo hypertension after liver transplantation. Hypertension 22(2), 257-267 (1993).
92. Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation 82(12), 1625-1628 (2006).
93. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl. 7(11 Suppl. 1), S13-S21 (2001).
94. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349(10), 931-940 (2003).
95. O'Riordan A, Wong V, McCormick PA, Hegarty JE, Watson AJ. Chronic kidney disease post-liver transplantation. Nephrol. Dial. Transplant. 21(9), 2630-2636 (2006).
96. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J. Am. Soc. Nephrol. 1(2), 162-179 (1990).
97. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin. Nephrol. 23(5), 465-476 (2003).
98. Butte JM, Devaud N, Jarufe NP et al. Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation. Obes. Surg. 17(11), 1517-1519 (2007).
99. Duchini A, Brunson ME. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 72(1), 156-159 (2001).
100. Tichansky DS, Madan AK. Laparoscopic Roux-en-Y gastric bypass is safe and feasible after orthotopic liver transplantation. Obes. Surg. 15(10), 1481-1486 (2005).
101. Campsen J, Zimmerman M, Shoen J et al. Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes. Surg. 18(12), 1625-1627 (2008).
102. Laryea M, Watt KD, Molinari M et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 13(8), 1109-1114 (2007). • Shows a high rate of metabolic syndrome and a high risk of related complications in liver transplant patients.
103. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 27(1), 103-107 (1997).
104. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif. Tissue Int. 69(6), 321-326 (2001).
105. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J. Clin. Endocrinol. Metab. 90(4), 2456-2465 (2005).
106. Compston JE. Osteoporosis after liver transplantation. Liver Transpl. 9(4), 321-330 (2003).
107. Haagsma EB, Hagens VE, Schaapveld M et al. Increased cancer risk after liver transplantation: a population-based study. J. Hepatol. 34(1), 84-91 (2001).
108. Herrero JI, Lorenzo M, Quiroga J et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl. 11(1), 89-97 (2005).
109. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 7(11 Suppl. 1), S109-S118 (2001).
110. Liu LU, Schiano TD. Long-term care of the liver transplant recipient. Clin. Liver Dis. 11(2), 397-416 (2007).
111. Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 77(2), 226-231 (2004).
112. Alonso O, Loinaz C, Moreno E et al. Advanced donor age increases the risk of severe recurrent hepatitis C after liver transplantation. Transpl. Int. 18(8), 902-907 (2005).
113. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 13(1), 21-29 (2007).
114. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122(4), 889-896 (2002).
115. 2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. 38(6), 567-572 (2003).
116. Levy G, Villamil F, Samuel D et al. Results of list, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 77(11), 1632-1638 (2004).
117. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 143(10), 722-728 (2005).
118. Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: emerging developments. Transpl. Immunol. 17(2), 108-113 (2007).
119. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl. Immunol. 17(2), 114-119 (2007).
120. Tryphonopoulos P, Tzakis AG, Weppler D et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am. J. Transplant. 5(3), 608-613 (2005).
121. Martinez-Llordella M, Lozano JJ, Puig-Pey I et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J. Clin. Invest. 118(8), 2845-2857 (2008).
122. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am. J. Transplant. 6(8), 1774-1780 (2006).